Healthy Japanese and Caucasian Male Adults Clinical Trial
Official title:
A Phase 1, Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of MLN1202 in the Japanese and Caucasian Healthy Male Participants
| Verified date | October 2016 |
| Source | Takeda |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Japan: Ministry of Health, Labor and Welfare |
| Study type | Interventional |
The objective of the study is to investigate the safety, pharmacokinetics, and pharmacodynamic effect of a single dose of MLN1202 in healthy Japanese male adults.
| Status | Withdrawn |
| Enrollment | 0 |
| Est. completion date | November 2015 |
| Est. primary completion date | November 2015 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Male |
| Age group | 20 Years to 45 Years |
| Eligibility |
Inclusion Criteria: 1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements. 2. The participant signs and dates a written informed consent form (ICF) prior to the initiation of any study procedures. 3. The participant is a healthy adult man who is defined as Japanese (all parents and grandparents of the participant are Japanese) or Caucasian (all parents and grandparents of the participant are Caucasian). 4. The participant is between 20 and 45 years of age at the time of informed consent. 5. The participant has a body weight of at least 50 kg and has a body mass index (BMI) between 18.5 and 25.0 kg /m2 when the participant is Japanese or between 18.5 and 30.0 kg /m2 when the participant is Caucasian at the time of screening and baseline examination. 6. A male participant who is sexually active with a female partner of childbearing potential and who has not received contraceptive therapy agrees to use adequate contraception from the time of informed consent until 12 weeks (84 days) after administration of the study drug. Exclusion Criteria: 1. The participant has received any other investigational compound within 16 weeks (112 days) prior to administration of the study drug. 2. The participant has previously received agents containing MLN1202, a monoclonal antibody or monoclonal antibody fragment. 3. The participant has been vaccinated within 4 weeks (28 days) prior to administration of the study drug or is planning to be vaccinated during the study period. 4. The participant is a study site employee or immediate family member of the employee, or may consent under duress. 5. The participant has poorly-controlled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, or endocrine disease, hemorrhagic disorder or other abnormalities which may impact the ability of the participant to participate or potentially confound the study results. 6. The participant has recurrent serious or poorly-controlled infection and is considered to have difficulty participating in the study by the investigator. 7. The participant has a history of hypersensitivity or allergies to MLN1202 or additives contained in MLN1202 preparations. 8. The participant has a history of hypersensitivity or allergies to monoclonal antibodies other than MLN1202. 9. The participant has positive results in urine drug tests at screening. 10. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol dependence within 2 years prior to the study visit at screening or is unwilling to agree to abstain from alcohol and drugs throughout the study period. 11. The participant requires any excluded medication or food products listed in the Excluded Medications and Dietary Products (see section 7.3) during the study period. 12. The participant intends to donate sperm during the study period or period until 12 weeks (84 days) after administration of the study drug. 13. The participant has a history of cancer. 14. The participant has, is suspected of having, or has a history of active tuberculosis or latent tuberculosis infection. 15. The participant has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis B virus antibody (hepatitis B surface antibody [HBsAb]/ hepatitis B core antibody [HBcAb]), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen, or serological reactions for syphilis at screening. This does not include the participant who has a positive test result only for HBsAb due to HBV vaccination. 16. The participant has used nicotine-containing products (cigarettes, pipes, cigars, chewing tobacco, nicotine patches, or nicotine gum, etc.) within 4 weeks (28 days) prior to administration of the study drug. 17. The participant has poor peripheral venous access. 18. The participant has undergone whole blood collection of at least 200 mL within 4 weeks (28 days) or at least 400 mL within 12 weeks (84 days) prior to administration of the study drug. 19. The participant has undergone whole blood collection of at least 800 mL in total within 52 weeks (364 days) prior to administration of the study drug. 20. The participant has undergone blood component collection within 2 weeks (14 days) prior to administration of the study drug. 21. The participant has any clinically significant electrocardiographic (ECG) abnormalities at the time of screening or baseline examination. 22. The participant has abnormal laboratory values that suggest a clinically significant underlying disease, or the participant has the following lab abnormalities at the time of screening or baseline examination: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 × the upper limits of normal, or differential white blood count (monocytes) < the lower limit of normal. The following criteria will be evaluated by laboratory tests at the screening: insulin (fasting), parathyroid hormone (PTH) (intact). 23. The participant has systolic blood pressure <80 mmHg or diastolic blood pressure <45 mmHg, or systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at the time of screening, baseline examination or examination prior to administration of the study drug. 24. The participant is receiving treatment for a wound and is, in the opinion of the investigator, unsuitable to participate in the study. 25. The participant is scheduled to undergo surgery within 12 weeks (84 days) after administration of the study drug. 26. In the opinion of the investigator, the participant is unlikely to comply with the protocol or is unsuitable for any other reasons |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Takeda |
Japan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Participants Reporting One or More Treatment-emergent Adverse Events | The adverse event is defined as any unfavorable and unintended sign, symptom, or disease that develops when a drug is administered, irrespective of the causal relationship to the drug. | Up to Day 37 | Yes |
| Secondary | Maximum observed serum concentration (Cmax) of MLN1202 | Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. | Up to Day 37 | No |
| Secondary | Area under the serum concentration-time curve (AUC) of MLN1202 in serum | Area under the serum concentration-time curve during a dosing interval. | Up to Day 37 | No |
| Secondary | Changes in serum monocyte chemoattractant protein-1 (MCP-1) concentrations | Serum MCP-1 concentrations will be measured at each protocol-specified time point, when blood samples are collected. | Up to Day 37 | No |
| Secondary | Changes in monocyte count from baseline | The absolute monocyte count will be determined at each protocol-specified time point, when blood samples are collected. | Up to Day 37 | No |